Back to the future: With increased scrutiny over price increases, the fundamentals of organic growth in biopharma are more important than ever

0
27

Price increases. This is arguably the most discussed topic in the biopharmaceutical industry today. In January, biopharmaceutical manufacturers raised list prices on more than 250 products.1 In July, 20 companies increased the list prices for more than 40 prescription drugs by an average of 13 percent.2 But are annual price increases a sustainable mechanism for driving future growth in biopharma?

The post Back to the future: With increased scrutiny over price increases, the fundamentals of organic growth in biopharma are more important than ever appeared first on Deloitte Center for Health Solutions.